Diffusion Pharmaceuticals Inc. (DFFN) |
|
0.4122 0.052 (14.5%)
|
02-28 16:00 |
|
Open: |
0.33 |
Pre. Close: |
0.36 |
|
High:
|
0.4274 |
Low:
|
0.315 |
|
Volume:
|
2,291,553 |
Market Cap:
|
14M |
|
|
|
|
Diffusion Pharmaceuticals Inc is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.43 - 0.433 |
0.433 - 0.435 |
|
Low:
|
0.305 - 0.308 |
0.308 - 0.31 |
|
Close:
|
0.405 - 0.41 |
0.41 - 0.414 |
|
Technical analysis |
as of: 2020-02-28 4:27:44 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 0.58 One year: 0.68 |
| Support: |
Support1: 0.38 Support2: 0.31 |
| Resistance: |
Resistance1: 0.50 Resistance2: 0.58 |
| Pivot: |
0.41  |
| Moving Average: |
MA(5): 0.39 MA(20): 0.42
MA(100): 0.63 MA(250): 2.10 |
| MACD: |
MACD(12,26): -0.02 Signal(9): -0.02 |
| Stochastic oscillator: |
%K(14,3): 26.70 %D(3): 18.31 |
| RSI: |
RSI(14): 47.65 |
| 52-week: |
High: 11.00 Low: 0.21 Change(%): -87.9 |
| Average Vol(K): |
3-Month: 332715 10-Days: 132088 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.DFFN has closed below upper band by 46.8%. Bollinger Bands are 80.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to DFFN's normal range. The bands have been in this narrow range for 55 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
2019-11-20
The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.
2019-11-19
The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Antares Pharma Inc (NASDAQ: ATRS ) Arvinas Inc (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Crispr Therapeutics AG (NASDAQ: CRSP ) DexCom, Inc. (NASDAQ: DXCM Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) )(announced a partnership with Novo Nordisk A/S (NYSE: NVO ) for developing RNAi therapies) Frequency Therapeutics Inc (NASDAQ: FREQ )(reacted to its third-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Karuna Therapeutics Inc (NASDAQ: KRTX )( announced positive results for its mid-stage schizophrenia drug) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) The Medicines Company (NASDAQ: MDCO )(announced full results of its ORION-9 Phase 3 study of inclisiran at the American Heart Association 2019 annual meeting) Medtronic PLC (NYSE: MDT ) Neurocrine Biosciences, Inc.
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
